Bactiguard Holding Ab · OMXSTO:BACTI_B
Bactiguard Holding Ab — Q3 2022 Earnings Presentation
17 slides from Bactiguard Holding Ab's earnings presentation, Oct 27, 2022
Slide 1: Investor presentation Q3 2022
Investor presentation Q3 2022 27 October, 2022 Anders Göransson, CEO Carin Jakobson, CFO
Slide 2: The need for infection prevention have never been greater
The need for infection prevention have never been greater 1 in every 10 patients worldwide affected by healthcare associated infections Source: Various news articles from this year 2
Slide 3: Bactiguard's vision: Keeping people safe from infections
Bactiguard’s vision: Keeping people safe from infections 3
Slide 4: Bactiguard – third quarter 2022
Bactiguard – third quarter 2022 Key Financials, Q3 2022 (Q3 2021) Revenue EBITDA Net Profit Operating cash flow MSEK 66.2 (45.2) • License 42.4 (30.1) MSEK 2.5 (1.2) MSEK -8.5 (-10.8) MSEK 9.9 (14.3) • BIP revenues 16.3 (13.2) Strong revenue growth of 46%, adjusted for currency effects 15% compared
Slide 5: Business Highlights – License revenue
Business Highlights – License revenue Another quarter with strong BD revenue and significant revenue from Zimmer Biomet and Dentsply Sirona License New license Q3 2022: Q3 2022: MSEK 34,8 (29,1) MSEK 7,6 (0,9) + 19%* NA%* • The underlying business is stable on an annual • Zimmer Biomet: Fees for con
Slide 6: Business Highlights – Zimmer Trauma
Business Highlights – Zimmer Trauma Good traction in EMEA launch, further evidence generation and regulatory work ZIMMER BIOMET TRAUMA • Zimmer® Natural Nail® (ZNN) Bactiguard-implants launch continues across EMEA, with Germany and Italy in the forefront • To validate the efficacy of our technology,
Slide 7: Two licence partners with products in the market
Two licence partners with products in the market BD with IC (Infection Control) Urinary Catheters and ZB with ZNN Bactiguard Trauma nail 1994 2021 1990 US 2019 EMEA • Foley catheters • Trauma implants Additional licence agreements signed with Smartwise in Sweden in 2017 and with Well Lead in China i
Slide 8: Significant work ongoing in the two recent agreements
Significant work ongoing in the two recent agreements License and new license business 1994 2021 1990 US 2019 EMEA 2022 • Foley catheters • Trauma implants • Hips and knees • Dental replacements • Sports medicine • Craniomaxillofacial • Thorax applications Additional licence agreements signed with S
Slide 9: Business Highlights – Bactiguard product portfolio
Business Highlights – Bactiguard product portfolio Growth in focus areas: BIP Urinary Catheters and Wound Care • Growth in focus products, amplified BACTIGUARD BIP PORTFOLIO by a positive currency effect, but below our ambition • Good momentum in Nordic, India and Q3 2022: Malaysia, while other mark
Slide 10: Right timing to fuel growth
Right timing to fuel growth Strong base and now expanded patent protection until 2039 1 2 3 Strong clinical evidence Capital for growth Commercial and Coating capabilities • >200 million catheters used with no • > 220 mSEK raised during the fall of • Strengthening commercial and coating reported adv
Slide 11: Rolling 12-month revenue
Rolling 12-month revenue • Rolling 12-months revenue numbers all-time high • License - BD volume stable on a high level - Growing business from Zimmer Biomet • BIP – Growing in focus markets • Good momentum in New license revenue from Zimmer Biomet and Dentsply Sirona 11
Slide 12: Financial overview
Financial overview Amounts in MSEK 2022 2021 2022 2021 2021 2021/22 Jan-Sep 2022 vs Jan-Sep 2021 Jul-Sep Jul-Sep Jan-Sep Jan-Sep Full year RTM • Revenue MSEK 181.3 (133) an increase of 36% though higher license revenue of Total revenues 66.2 45.2 181.3 133.0 179.0 227.4 31% and 20% higher BIP revenu
Slide 13: Liquidity
Cash flow and liquidity Cash and cash equivalent 300 40 • Cash flow from operating activities was 9.9 MSEK (14.3) 250 30 • SEB Overdraft facility unutilized, • Available liquidity incl. overdraft 200 20 facility 234.8 (280.5) MSEK Liquidity 150 10 Cash flow 100 0 * New share issue of MSEK 228 before
Slide 14: There are three key growth drivers in our fight against infections
There are three key growth drivers in our fight against infections Illustrative * Now Existing license customers * Currently a global development partnership with a license option
Slide 15: Ten reasons to invest in Bactiguard
Bactiguard infection prevention – Safe and Effective Ten reasons to invest in Bactiguard Long-term owners and Contribution to the UN’s Global dedicated management 10 1 Sustainable Development Goal. Scalable business Bactiguard technology model 9 2 - effective and safe Financial Target 2026: • Revenu
Slide 16: Questions & Answers
Questions & Answers Anders Göransson Carin Jakobson Gabriella Björknert Caracciolo CFO CEO +46 8 440 58 80 +46 8 440 58 80 anders.goransson@bactiguard.com carin.jakobson@bactiguard.com 16
Slide 17: Bactiguard on the outside – safe on the inside
Bactiguard on the outside – safe on the inside 17 17